Artivion 3Q 2026: Revenue $123.79M, EPS ($0.16) — 10-Q Summary
Artivion reported 3Q 2026 revenue of $123.79M, up 9% YoY, but a net loss of $0.16 per share. Growth in aortic stent grafts and On-X products drove revenue, while higher costs and expenses pressured margins and results.
How this was made
The 30-second read
Why it matters
The earnings release introduces new financial metrics that could affect valuation and short‑term price action.
Market read
The earnings miss may trigger a sell‑off in Artivion and could influence sentiment toward similar medical‑device stocks.
What to watch
Potential upcoming regulatory approvals for On‑X products could improve future margins.
Background
Artivion's 10‑Q details Q3 performance, highlighting growth in aortic stent grafts and On‑X products but also higher costs and a shift to loss.
Ticker impact
Artivion reported Q3 2026 revenue of $123.79M and a net loss of $0.16 EPS, a fresh earnings disclosure.
likely downside as market prices in the unexpected loss
Revenue grew modestly but the swing to a loss signals margin pressure and higher operating costs.
Market effects
May weigh on other aortic device makers as margin pressure is highlighted.
Limited to US biotech/medical device sector.
Low, confined to niche medical device space.
Counterpoint
If the revenue growth accelerates in Q4, the loss could be a temporary blip.
Key entities
- CompanyArtivion, Inc.
Medical device manufacturer focused on aortic and heart valve technologies.
